Andrew Calam

Andrew has over 25 years of experience in the life sciences industry, holding management and executive positions in both the CRO and biotechnology sector, supporting pharmaceutical development. Andrew started his career within the bioanalytical space before focusing on project management, leading multinational teams responsible for all aspects of clinical trial management in Phase I to Phase III trials. Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and management of several clinical programs for targeted cancer therapies. Andrew holds a BSc in Environment Chemistry from Leeds University.